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Abstract
We describe two Malawian adults on successful antiretroviral therapy who experienced frequent malaria episodes after stopping cotrimoxazole 
prophylaxis. We argue that, in addition to stopping cotrimoxazole, diminished malaria immunity and drug interactions between efavirenz and artemether–
lumefantrine may have played a causative role in the recurrent malaria our patients experienced.
Introduction
Recurrent malaria illness is uncommon in non-pregnant 
adults living in endemic areas, owing to protection conferred 
by naturally acquired immunity.1,2 HIV-associated immune 
suppression contributes to increased frequency and severity 
of  clinical malaria illness in malaria-experienced adults,3,4 
but the combination of  antiretroviral therapy (ART), 
cotrimoxazole preventative therapy (CPT) and insecticide-
treated bed net use is highly effective in preventing malaria 
in persons living with HIV.5,6 CPT provides a survival benefit 
to patients with HIV infection by preventing severe bacterial 
and parasitic infections, although its exact role for patients 
on successful ART in sub-Saharan Africa remains uncertain.7 
We report 2 case histories of  Malawian adults on ART and 
CPT who experienced repeated episodes of  malaria illness 
soon after stopping CPT and discuss potential contributing 
factors.
Case 1
A 49-year-old woman was on the standard first-line ART 
regimen of  tenofovir, lamivudine, and efavirenz, along with 
CPT for 7 years before enrolment in “A randomized, open-
label controlled trial of  daily trimethoprim-sulfamethoxazole 
or weekly chloroquine among adults on antiretroviral 
therapy in Malawi”. This study examines whether there is a 
benefit of  lifelong CPT, as recommended by current WHO 
and Malawi guidelines, for patients with excellent clinical, 
immunological, and virological responses to ART.7 She had a 
CD4 count of  461 cells/µL and undetectable HIV-1 RNA at 
baseline. She was randomised to the arm without prophylaxis 
and CPT was discontinued. Four weeks later, she developed 
intermittent fevers, headache, and malaise. On examination, 
tachycardia (113 beats per minute) and tachypnoea (24 
breaths per minute) were noted, while other vital signs 
and the rest of  the physical examination were normal. A 
blood film showed Plasmodium falciparum (Figure 1A) with a 
parasite density of  2480/mm3. A full blood count showed 
no abnormalities and blood cell morphology was normal on 
a peripheral blood smear. She was treated with artemether–
lumefantrine (80/480 mg tablets), 4 tablets twice a day for 
3 days;  her response was  evaluated using the standardised 
World Health Organization (WHO) methods for surveillance 
of  antimalarial drug efficacy, with follow-up visits on days 1, 
2, 3, 7, 14, 21 and 28.8 She completed malaria treatment with 
good self-reported adherence, was parasite-free from day 2 
through day 28, and symptoms had resolved by day 3. One 
month after day 28 she presented with new-onset fever, and 
malaria smear showed P. falciparum with a density of  7720/
mm3. She was treated with artemether–lumefantrine again. 
On day 2 she was afebrile and no parasites were seen on 
blood films from day 2 through day 28. Six weeks later, she 
returned with fever, headache, and malaise. The blood film 
showed Plasmodium ovale with a parasite density of  120/
mm3 (Figure 1B), and she was treated with artemether–
lumefantrine for a third time. Symptoms resolved quickly 
and blood smears from day 2 through day 14 were negative 
for parasites. A glucose 6-phosphate dehydrogenase (G6PD) 
test revealed that she was deficient and treatment with 
primaquine was not given. On day 21 she was asymptomatic, 
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Figure 1: A. Plasmodium falciparum trophozoite 
B. Plasmodium ovale trophozoite
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Such longstanding protection against blood stage infection 
may lead to waning of  naturally acquired immunity to 
malaria and increased vulnerability to malaria infection and 
illness when CPT is discontinued. The observation that 
long-term CPT in HIV-exposed, uninfected children led to 
reduced development of  IgG anti-malarial antibodies10 and 
the experience that adults who move from highly endemic- 
to non-transmission areas become susceptible to severe 
malaria upon return to their original residence12 support 
the hypothesis that CPT discontinuation after its prolonged 
and consistent use can lead to frequent malaria attacks as a 
rebound effect due to decreased naturally acquired immunity. 
Malaria treatment failure is defined as failure to clear 
malarial parasitaemia or to resolve clinical symptoms after 
treatment with antimalarial drugs.13 This can be due to 
subtherapeutic exposure to antimalarial drugs or due to 
drug-resistant parasites. In all episodes described here, 
malaria parasitaemia was rapidly and completely cleared after 
artemether–lumefantrine treatment. The patients were in 
good general health, had close to normal CD4 counts, and 
no gastrointestinal symptoms suggesting HIV enteropathy. 
They reported consistent bednet use, full adherence to 
antimalarial treatment, and did not vomit at any point. 
These arguments make it likely that treatments were taken as 
prescribed and were well-absorbed. 
In Malawi, standard first-line ART regimens include efavirenz 
and nevirapine, and artemether–lumefantrine is the first-
choice antimalarial drug. These 4 drugs are all metabolised by 
enzymes in the cytochrome P450 system (CYP450) in the liver 
and concomitant use of  these antiretroviral and antimalarial 
drugs may affect malaria treatment. Lumefantrine has a long 
half-life (3 to 6 days) and clears residual parasitaemia with 
the aim to prevent recrudescence when used in combination 
with artemether.14 Lumefantrine is metabolised by CYP450 
enzyme 3A4 (CYP3A4). Efavirenz is also metabolised 
by CYP3A4, as well as by CYP2B6 and CYP2A6, and 
efavirenz induces the activity of  these 3 enzymes in a 
dose-dependent manner. Some individuals are genetically 
determined slow metabolisers of  efavirenz, mainly due to 
single-nucleoside polymorphisms in CYP2B6, and they 
maintain high efavirenz levels and high-level induction 
of  CYP3A4 as a consequence.14-18 CYP3A4 induction by 
efavirenz enhances lumefantrine metabolism, which may 
but a blood film showed P. falciparum with parasite density of  
320/mm3. A fourth treatment with artemether–lumefantrine 
was started; parasitaemia resolved by day 7 and remained 
negative through day 28. She reported being fully adherent 
to all antimalarial treatments and denied vomiting any doses. 
Blood cultures taken during the first 3 presentations yielded 
no growth. Real-time polymerase chain reaction (PCR) 
analysis of  dried blood spot specimens collected at all visits 
confirmed the species identified by microscopy and excluded 
mixed infections.
Case 2
A 37-year-old woman was enrolled into the same trial as the 
first patient, after having been on tenofovir, lamivudine, and 
efavirenz, with CPT, for 3 years. Her CD4 count at enrolment 
was 883 cells/µL, and HIV-1 RNA was undetectable. She 
was also randomised to no prophylaxis arm, and CPT was 
discontinued. Starting 2 weeks after CPT discontinuation 
and over a period of  7 months, she experienced 6 malaria 
epiodes and was found to have asympomatic parasitaemia 
on one occasion during routine follow-up, as summarised 
in Table 1. Findings from physical examination during each 
episode were unremarkable. This patient also reported 
complete adherence to antimalarial treatments and denied 
vomiting during any malaria episode. Only P. falciparum 
species were observed in microscopy, but molecular analysis 
was not performed for this patient. Due to the frequent 
recurrences of  malaria illness, the study team decided to 
resume CPT in this patient.
Discussion
Both adult patients experienced frequent malaria episodes 
within the months following CPT discontinuation. 
Recurrent malaria infection after treatment can be the result 
of  3 different circumstances: malaria treatment failure 
(recrudescence), activation of  hepatic hypnozoites of  ovale 
or vivax malaria (relapse), or new infection (reinfection). 
Because cotrimoxazole provides malaria prophylaxis,5,6,9 
discontinuing CPT increases individual susceptibility to 
malaria illness. We consider additional reasons why our 
patients had frequently recurring malaria episodes.
In HIV-infected adults living in regions with high malaria 
burden, ART, CPT, and insecticide-treated bed net use 
effectively reduce incident malaria infection and illness.5,6,9,11 











Interval to parasite 
clearance by 
microscopy (days)
Events during 28 day follow up
1 2nd May 2016 120 2 2
Symptomatic parasitaemia day 23 
2 26th May 2016 6640 3 3
Symptomatic parasitaemia day 28 
3 23rd June 2016 400 3 3
None  
4 23rd Aug 2016 3880 3 3
None 
5 10th Oct 2016 17,600 3 2
Asymptomatic parasitaemia day 28 
6 7th Nov 2016 14,160
Asymptomatic 
on day 0
2 Symptomatic parasitaemia day 25 (parasite count 280/mm3)
7 2nd Dec 2016 280 7 1 None
l  : Summary of mal ria episodes for Case 2
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lead to plasma concentrations that are subtherapeutic14,15 and 
which may then decrease the clinical efficacy of  artemether–
lumefantrine. Late treatment failures have been previously 
reported in patients with high baseline parasitaemia and 
low lumefantrine concentrations.19 There are also drug 
interactions between efavirenz and artemether, and between 
nevirapine and artemether–lumefantrine, but these appear 
to be of  less clinical relevance.15 Further insight into the 
role of  these mechanisms in our patients could have been 
gained by determining plasma lumefantrine and efavirenz 
levels and by pharmacogenetic analysis looking for CYP2B6 
polymorphisms—tests that are not available in our setting. 
Despite adequate adherence to the artemether–lumefantrine 
dosing, our patients may have had insufficient exposure to 
lumefantrine, and this would have contributed to treatment 
failure.
Drug resistance is another cause of  treatment failure, but 
clinical or parasitological failures of  artemisinin drug 
combinations have not been reported from Malawi and none 
of  the relevant resistance-conveying mutations (in particular, 
in the kelch propellor gene domain) have been found in P. 
falciparum on the African continent.20
Case 2 had recurrent malaria late within the 28-day treatment 
follow-up period (2nd, 3rd, 6th and 7th episodes), but we 
did not perform P. falciparum genotyping to distinguish 
reinfection from recrudescence. We can therefore not 
definitively determine if  malaria treatment failure occurred 
in these episodes.
P. ovale infection occasionally occurs in Malawi and can cause 
relapses due to the persistence of  hypnozoites in the liver. Case 
1 had such an episode, and while artemether–lumefantrine 
is adequate treatment for P. ovale blood stages, primaquine 
is required to treat the hypnozoites. We identified G6PD 
deficiency in Case 2, and thus did not prescribe primaquine, 
which is associated with haemolysis and increased risk of  
cerebrovascular accident in persons with G6PD deficiency. 
P. ovale relapse did not appear to play a role in our second 
case.
Conclusions
Several potential factors can explain why HIV-infected 
patients experience recurrent malaria illness episodes 
after stopping CPT: poor adherence to antimalarial drugs; 
vomiting tablets; malabsorption due to HIV enteropathy; 
antimalarial drug resistance; P. ovale hypnozoite relapse; 
waning of  acquired malaria immunity under long-term use 
of  bed nets and effective ART and CPT; and drug–drug 
interactions between lumefantrine and efavirenz. Only the 
last 2 are likely to have contributed in our cases. Previous 
clinical trials have demonstrated that CPT protects against 
uncomplicated malaria in African adults on ART, without 
providing evidence of  benefit in terms of  survival, other 
morbidity, and HIV-related outcomes.9,11 The study in which 
both our patients are enrolled will provide conclusive insight 
into the role of  CPT in clinically stable adults on effective 
ART.
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